title: Synergistic effect between lipoprotein lipase and apolipoprotein C3 genes in determining the severity of coronary artery disease.
abstract: A number of genetic variants have been identified in the lipoprotein lipase (LPL) gene. We aimed to investigate the possible associations between LPL gene and apolipoprotein C3 (APOC3) gene polymorphisms with coronary artery disease (CAD) and its severity, as well as the interaction between these polymorphisms and classical risk factors. The HindIII variant of LPL and APOC3 were genotyped in 156 CAD patients and 154 subjects as a control group. We found that the odds ratio (OR) estimating the effect of joint exposure to H2H2 genotype of LPL and S2S2 genotype of APOC3 was significantly higher than the OR estimating the effect of each factor in the absence of the other. The present study points to a synergistic interaction between H2H2 genotype of LPL gene and S2S2 genotype of APOC3 gene that leads to increased severity of CAD. Smoking, low HDL, and diabetes increased the severity of CAD in patients carrying these risky genotypes.
authors: Cardiology Department, Faculty of Medicine, Zagazig University, Zagazig, Egypt.
authors: Tarek A
authors: TA
authors: Abd-El-Aziz
authors: Randa H
authors: RH
authors: Mohamed
authors: Amal S
authors: AS
authors: El-Shal
mesh_terms: D000328:Adult; D053305:Apolipoprotein C-III / Q000235:genetics*; D016022:Case-Control Studies; D016009:Chi-Square Distribution; D003324:Coronary Artery Disease / Q000175:diagnosis / Q000201:enzymology / Q000235:genetics*; D005787:Gene Frequency; D020022:Genetic Predisposition to Disease; D014644:Genetic Variation; D006801:Humans; D008071:Lipoprotein Lipase / Q000235:genetics*; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D010641:Phenotype; D012044:Regression Analysis; D012307:Risk Factors; D012720:Severity of Illness Index
chemical_list: D053305:Apolipoprotein C-III; C548261:LPL protein, human; D008071:Lipoprotein Lipase
references: J Lipid Res. 1992 Jul;33(7):1067-72
references: 1358995
references: Am J Epidemiol. 1974 Jun;99(6):385-8
references: 4841816
references: J Lipid Res. 2000 Apr;41(4):521-31
references: 10744772
references: Circulation. 2008 Aug 12;118(7):702-4
references: 18695202
references: Eur J Clin Invest. 1998 Oct;28(10):807-12
references: 9792993
references: Methods Enzymol. 1996;263:32-60
references: 8748999
references: Br Heart J. 1992 Jul;68(1):60-6
references: 1355351
references: J Lipid Res. 1996 Apr;37(4):693-707
references: 8732771
references: Circulation. 2006 Feb 7;113(5):691-700
references: 16461842
references: Coll Antropol. 2006 Sep;30(3):549-54
references: 17058522
references: J Am Coll Cardiol. 2004 Nov 2;44(9):1819-24
references: 15519013
references: Eur J Clin Invest. 1982 Apr;12(2):113-20
references: 6807682
references: J Lipid Res. 1992 Jul;33(7):995-1003
references: 1431591
references: Arteriosclerosis. 1982 May-Jun;2(3):208-15
references: 6979996
references: Circulation. 1999 Jun 8;99(22):2901-7
references: 10359734
references: Atherosclerosis. 2001 Sep;158(1):173-81
references: 11500189
references: Clin Chem. 1972 Jun;18(6):499-502
references: 4337382
references: Eur J Clin Invest. 1998 Jul;28(7):584-91
references: 9726040
references: Pharmacol Ther. 1996;70(2):101-35
references: 8843465
references: Mol Cell Biochem. 2011 Aug;354(1-2):141-50
references: 21499891
references: Genet Mol Res. 2010 Jan 19;9(1):89-96
references: 20108206
references: Biochim Biophys Acta. 1992 May 8;1125(3):297-304
references: 1596518
references: Atherosclerosis. 1991 Mar;87(1):75-86
references: 1678604
references: Atherosclerosis. 1999 Jul;145(1):187-95
references: 10428310
references: Arterioscler Thromb. 1994 Jul;14(7):1090-7
references: 7912549